SAN DIEGO — Data presented at the American Society of Hematology meeting suggest sponsors are making inroads in development of drugs that elicit responses in the hard-to-treat acute myeloma leukemia, but survival is still the higher hurdle for success.
Stemline Therapeutics Inc., Seattle Genetics Inc. and Karyopharm Therapeutics Inc